Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment by Yun-Ming Tian et al.
Tian et al. Radiation Oncology 2013, 8:272
http://www.ro-journal.com/content/8/1/272RESEARCH Open AccessPrognostic factors in nasopharyngeal carcinoma
with synchronous liver metastasis: a retrospective
study for the management of treatment
Yun-Ming Tian1†, Lei Zeng1†, Feng-Hua Wang1†, Shuai Liu1, Ying Guan1, Tai-Xiang Lu1 and Fei Han1,2*Abstract
Purpose: To retrospectively analyze the prognosis of patients with nasopharyngeal carcinoma (NPC) initially
presenting with liver metastasis, in order to identify independent prognostic factors to facilitate management of
treatment.
Methods: Eighty-five patients with untreated NPC and synchronous liver metastasis, initially diagnosed between
January 2000 and December 2009, were selected for this retrospective study. Seventy-eight received systemic
chemotherapy, 32 underwent subsequent radiotherapy of the primary tumor, and 18 received local therapy for
metastatic lesions. Clinical features, laboratory parameters and treatment modalities were compared by univariate
and multivariate analyses.
Results: The median survival time was 19.0 months and the 3-year overall survival rate was 14.1%. The overall
response and disease control rates were 70.4% and 86.4%, respectively. Significant predictors of short survival were
KPS ≤ 70 (P = 0.03), serum lactate dehydrogenase levels >245 IU/l (P = 0.01) and poor response to chemotherapy
(P < 0.01). In contrast, significantly longer survival rates were achieved by patients having at least six chemotherapy
cycles compared to those receiving <6 cycles (3-year OS: 18.3% vs. 7.1%; P < 0.01), and patients receiving radiotherapy
of the primary tumor following complete or partial response to chemotherapy (3-year OS: 30.8% vs. 3.8%, P < 0.01).
Conclusions: Five key independent factors were identified and sub-classified as potential prognostic indicators for NPC
with liver metastases. Progressive treatments of systemic chemotherapy and radiotherapy at the primary tumor could
prolong survival in the subset of patients having fewer negative prognosticators.
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Nasopharyngeal carcinoma (NPC) is a disease with a dis-
tinct racial and geographical distribution, with the highest
incidence rate in Southeast Asia. NPC is biologically dif-
ferent from other squamous cell cancers of the head and
neck, with approximately 95% classed as undifferentiated
carcinomas (WHO stage III). It also has the highest pro-
pensity for lymphatic spread and distant metastases [1-4].* Correspondence: hanfei@sysucc.org.cn
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reproduction in any medium, provided the orOver 70% of patients with NPC have neck masses of 6%-
15% and present with synchronous distant metastasis at
initial diagnosis, the most common sites being bone, lung
and liver [5-7]. Several reports have indicated that liver
metastasis may be an independent negative prognostic
factor compared to bone or lung metastasis [8-12].
Studies relating to NPC with liver metastasis are limited,
and few distinguish between patients with synchronous
liver metastasis and those who develop liver metastasis fol-
lowing treatment. Patients presenting with NPC and liver
metastasis at initial diagnosis undergo different treatment
regimens, and have different survival rates, compared to
those with subsequent liver metastasis [13]. Although pal-
liative chemotherapy has been shown to achieve high ob-
jective response rates, recurrence frequently occurs after. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy of the primary tumor and metastatic liver lesions
remains controversial [14-16].
The purpose of this study was to identify potential
prognostic factors in NPC with synchronous liver metas-
tasis by retrospectively analyzing patients’ clinical charac-
teristics, treatment modalities and survival. The results
could contribute to future management.Materials and methods
Patients and selection criteria
Patients with NPC presenting with liver metastasis at
initial diagnosis were referred to Sun Yat-Sen University
Cancer Center between January 2000 and December
2009. The selection criteria were as follows: pathologic-
ally confirmed NPC in the nasopharynx; diagnosis of
liver metastasis based on physical examination and
imaging; adequate renal function as demonstrated by a
creatinine clearance rate of ≥60 mL/min; complete
follow-up and clinical data, including laboratory and im-
aging data. Patients with other malignancies or unstable
cardiac disease requiring treatment were excluded.Baseline and treatment evaluations
Each patient received a pretreatment evaluation which in-
cluded complete history, physical examination, hematology
and biochemistry profiling including liver and renal func-
tions, Epstein-Barr virus serology, chest radiographs, sonog-
raphy and CT of the abdomen, whole-body bone scan and
MRI of the nasopharynx and neck. Imaging of the abdomen
was performed after every two courses of chemotherapy,
and then every 3 months during follow-up. The median
follow-up period was 17.0 months. Survival status was veri-
fied on December 31, 2012, by direct telecommunication
with the patient or their family and by checking the clinic
attendance records.Clinicopathological, laboratory and survival assessments
Overall survival (OS) was measured from diagnosis until
the date of death from any cause. Patients were censored
if remained alive at the time of the last follow-up. Ob-
jective response was measured according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST).
Patients’ characteristics including Karnosky performance
score (KPS), gender and age; laboratory parameters in-
cluding alanine aminotransferase (ALT), hemoglobin,
lactate dehydrogenase (LDH) and alkaline phosphatase
(ALP); metastatic characteristics including number, size,
response to chemotherapy and existence of extrahepatic
metastasis; treatment criteria including number of che-
motherapy cycles, radiotherapy of the primary tumor
and local therapy of metastatic lesions were analyzed.Statistical analysis
OS was estimated by the Kaplan-Meier method. Statistical
significance between survival curves was analyzed using
the log-rank test. Multivariate analyses were performed
using the Cox proportional hazards model to test for inde-
pendent significance by backward elimination of insignifi-
cant explanatory variables. Covariates included patients’
characteristics, laboratory parameters, metastatic features
and treatment criteria. The response rates were compared




Out of the 91 patients who were initially referred to our
center, six were excluded due to missing clinical or
follow-up data. The clinicopathological data of the
remaining 85 patients are presented in Table 1.
Treatment regimens and response
The treatment modalities, including response to chemo-
therapy, are described in Table 2. Seven patients refused
treatment. The treatment modalities of the remaining 78
patients were determined according to the experience of
our center and the acceptance of the patients. All 78
were treated with platinum-based chemotherapy. The
median number of cycles was 6 (range: 1-15). A total of
32 patients received radiotherapy following chemother-
apy. Radiotherapy of the primary tumor was generally
administrated to those patients who achieved disease
control of the metastatic lesions after chemotherapy. It
was also administered to reduce serious symptoms
caused by the primary tumor that affected the quality of
life. Radiotherapy included treatment to the primary
tumor and to the superclavicular lymph nodes; 26 pa-
tients received a radiation dose ≥66 Gy and six patients
received a dose <66 Gy. Local therapy to metastases, in-
cluding radiofrequency ablation (RFA), interventional
embolization and liver radiotherapy (54 Gy/27f ), was ad-
ministered in 18 patients.
Toxicity
None of the patients exhibited grade V toxicity (death)
during chemotherapy. However, 54.5% developed grade
III–IV leucopenia or neutropenia, 28.5% developed grade
II–III mucositis and 19.5% exhibited grade II–III toxicity
with vomiting and nausea.
Response and overall survival
Four patients were omitted from further assessments as
imaging evaluations had not been performed after the
first cycle of chemotherapy. Of the remaining 74 pa-
tients, 4/74 (5.4%) achieved complete response (CR), 48/
74 (64.8%) achieved partial response (PR), 12/74 (16.2%)
Table 1 Clinical characteristics
Characteristics N (%)







Median age 50 (28-75)






Lactate dehydrogenase (LDH) (IU/l)
>245 54 (63.5)
≤245 31 (36.5)










No. of metastatic lesion
≤3 35 (41.2)
>3 50 (58.8)
































PF: Cisplatin + 5-Fu; TPF: Cisplatin + 5-Fu + Paclitaxel; TP: Cisplatin + Paclitaxe;
RFA: Radiofrequency ablation.
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sive disease (PD). The overall response and disease con-
trol rates were 70.4% and 86.4%, respectively.
Seventy-eight patients had died by the final evaluation
date (December 31, 2012). The main cause of death was
progression of metastatic lesions, which occurred in 74/
78 (94.9%) patients; 3/78 (3.8%) patients died of local
failure and 1/78 (1.3%) died of cardiac disease. The me-
dian survival time for all the patients was 19.0 months(range: 4-124 months). The 1-year, 2-year and 3-year
survival rates were 71.8%, 34.1% and 14.1%, respectively.
Long-term disease-free survival (>36 months) was achieved
by five patients; their clinical characteristics are sum-
marized in Table 3.
Univariate analyses
The results of the univariate analyses are summarized in
Table 4. The negative prognostic factors for OS were as
follows: KPS ≤70 (P < 0.01); LDH >245 IU/l (P < 0.01);
ALT >40 IU/l (P < 0.01); number of metastatic lesions >3
(P = 0.01); occurrence of extrahepatic metastasis (P =
0.01); number of chemotherapy cycles <6 (P = 0.01); no
response to chemotherapy (P < 0.01); no radiotherapy of
the primary tumor (P < 0.01); and no local therapy of
metastatic lesions (P=0.05).
The following factors were significantly associated with
poor response to chemotherapy: KPS ≤70 (P = 0.03);
LDH >245 IU/l (P < 0.01); number of metastatic lesions >3
(P = 0.02); occurrence of extrahepatic metastasis (P = 0.04);
and number of chemotherapy cycles <6 (P = 0.01).













29y 90 160 One PF × 9 cycles 2D-RT RFA 124
70 Gy/35f
40y 80 251 Four PF × 10 cycles 2D-RT No 117
70 Gy/35f
52y 90 206 Two TP × 6 cycles 2D-RT RFA 94
74 Gy/37f
65y 90 157 One TPF × 6 cycles 2D-RT RFA 91
70 Gy/35f
55y 80 206 Five PF × 6 cycles IMRT No 54
68 Gy/30f
2D-RT: Two-Dimensional radiotherapy; IMRT: Intensity Modulate Radiotherapy.
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The multivariate analysis results are summarized in
Table 5. Significant factors for poor prognosis were
KPS ≤70 (P = 0.04); LDH >245 IU/l (P = 0.01); no radio-
therapy of the primary tumor (P < 0.01); number of
chemotherapy cycles <6 (P < 0.01); and no response to
chemotherapy (P < 0.01). These results are demon-
strated in Figure 1.
Subgroup analysis showed that treatment with chemo-
therapy was also a positive prognostic factor for patients
with KPS ≥ 80 (19.0% vs 10.7%, P = 0.02), however, no
statistical significance was in patients with KPS ≤ 80 (P =
0.88). Significantly improved survival was also achieved
by radiotherapy of the primary tumor in patients who
achieved CR or PR after chemotherapy of metastatic le-
sions (30.8% vs. 3.8%, P < 0.01). In contrast, no signifi-
cant difference was observed for patients with SD.Table 4 Univariate analysis of variables correlated with overa
Characteristic 3-year OS (%
KPS: ≤70/>70 0.0 (16.2)
Gender: male/female 11.5 (28.6)
Age: >50/≤50 years 12.5 (15.6)
ALT(IU/I): >40 /≤40 3.8 (18.6)
Hemoglobin (g/L): <120/≥120 9.1 (14.9)
LDH (IU/I): ≥245/<245 9.3 (22.6)
ALP (IU/I): ≥110/<110 6.9 (16.1)
Number of lesions: >3/≤3 6.0 (25.7)
Size of lesions (cm): >3/≤3 6.3 (18.9)
Extrahepatic metastases: yes/no 2.8 (22.4)
Radiotherapy of primary tumor: no/yes 5.7 (28.1)
Cycles of chemotherapy: (1-5) vs. ≥6 8.6 (18.6)
Response to chemotherapy: no/yes 0.0 (19.2)
Local therapy of lesions: no/yes 10.4 (27.8)
astatistically significant; HR: hazard ratio; CI: confidence interval.Discussion
Liver metastasis is a common occurrence at initial diag-
nosis in patients with metastatic NPC. The survival time
in these patients is poor, ranging between 13.0 and
17.0 months [8-10]. Similar to these reports, our ana-
lyses gave a median survival time of 19.0 months, and a
3-year OS rate of 14.1%, which is lower than those re-
ported for lung or bone metastasis [11,12].
The benefits of systemic chemotherapy have been
demonstrated in many studies [14-18]. Platinum-based
combination treatment with two or three drugs achieves
high response rates and is the most widely used regimen
[17]. In this study, the patients who received chemother-
apy had a median survival time of 20.0 months, com-
pared to 9.0 months in patients who refused treatment.
In cases of metastatic NPC where chemotherapy is the
only curative option, it is important that patientsll survival















Table 5 Multivariate analysis of variables correlated with
overall survival
Characteristic HR (95% CI) P-value
KPS: ≤70/>70 2.21 (1.1-4.90) 0.04
LDH (IU/I): ≥245/<245 2.09 (1.12-3.67) 0.01
Cycles of chemotherapy: (1-5) vs. ≥6 3.02 (1.65-5.56) <0.01
Response to chemotherapy: no/yes 2.22 (1.29-3.49) <0.01
Radiotherapy to primary tumor: no/yes 2.87 (1.61-5.10) <0.01
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sufficient number of cycles. A retrospective study involv-
ing 20 long-term disease-free survivors with metastatic
NPC showed that approximately six cycles of chemother-
apy were required [14]. Wang et al. also found that pa-
tients who received six cycles of chemotherapy survived
longer than those receiving fewer cycles. Furthermore,
they showed that the number of chemotherapy cycles was
an independent prognostic factor in metastatic NPC [18].
Our results, based on univariate and multivariate analyses,
were consistent with both these reports, however due to
the retrospective nature of our study, further confirmation
is required.
The application of radiotherapy to the primary tumor in
NPC patients with synchronous liver metastasis remains
controversial. It is generally considered unnecessary due to
their short life expectancy and serious late complications.
However, due to improvements in techniques, several stud-
ies have demonstrated that local control of primary tumors
through radiotherapy can improve quality of life and con-
tribute to prolonged survival. Yeh et al. showed that the 2-Figure 1 Overall survival rates according to KPS (A), LDH (B), radiothe
and the response to chemotherapy (E).year OS rate in patients with metastatic NPC at diagnosis
was 24.0% when they received radiotherapy alone, com-
pared to 10% in those who received chemotherapy alone
[6]. They also showed that local control of the primary
tumor reduced necrosis, bleeding, nasal obstruction and se-
vere headaches. Our study supported these findings by
showing improved survival rates in patients who responded
to chemotherapy of the metastatic lesions when radiother-
apy of the primary tumor was administered. Taken together,
these findings indicate that better local control may help re-
duce the tumor burden and lower the risks caused by pro-
gression or recurrence in NPC.
Local therapy of metastatic lesions may also prolong
survival. Although local therapy is widely applied in pa-
tients with liver metastasis from colorectal cancer [19,20],
its application in metastatic NPC remains limited. Pan
et al. reported that the median survival of 11 patients with
1–3 metastatic lesions receiving treatment with RFA was
48.1 months, which was higher than those not receiving
RFA [13]. Furthermore, procedure-related complications
were infrequent. The treatment regimens for local therapy
of liver metastases analyzed in this study included RFA,
interventional embolization and liver radiotherapy. The
median survival for all three modalities was 23.0 months
and included three long-term disease-free survivors. RFA
was found to be more effective than both interventional
embolization and liver radiotherapy, giving a median sur-
vival time of 32.0 months compared to 9.0 months; how-
ever, this difference may be related to other factors
between the patients. Patient with 1-3 metastatic lesions
were found to benefit the most from RFA, with a medianrapy of primary tumor (C), number of cycles of chemotherapy (D)
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those not undergoing RFA. Therefore, local therapy to
metastatic liver lesions, particularly with RFA, should be
considered in patients with NPC who have ≤3 lesions to
further improve their survival when the primary tumor
and metastatic diseases are stable.
Patients’ response to chemotherapy was found to be a
significant prognostic factor. The overall response rate
was 76.4% and was associated with performance status,
LDH level, number of metastatic lesions, presence of
extrahepatic metastasis and number of chemotherapy
cycles, suggesting that these factors could be potential pre-
dictors of treatment response. Patients with LDH >245
IU/L, multiple organ metastasis and >3 liver lesions had
lower rates of CR or PR to chemotherapy. In clinical prac-
tice, the response of metastatic lesions to chemotherapy is
a key consideration in the choice of treatment; therefore,
patients with CR or PR were recommended for radiother-
apy of the primary tumor as this could significantly im-
prove survival.
LDH is a glycolytic enzyme which reversibly catalyzes
pyruvate to lactic acid under anaerobic conditions. Ele-
vated levels of LDH are considered a negative prognostic
factor in many solid tumors, including advanced NPC,
and have been associated with large tumor burden,
tumor extension and high risk of metastasis [21-25].
Serum LDH levels twice normal levels are rarely seen in
loco-regional disease but are commonly observed in
NPC patients with liver metastasis or multiple organ
metastases. As such, they have been described as a nega-
tive prognostic factor [23]. Studies have found that pa-
tients with advanced NPC and elevated baseline LDH
levels were more likely to develop liver metastasis fol-
lowing treatment [24], and elevated LDH levels were re-
ported in over 55.0% of patients with metastatic NPC,
with hazard ratios up to 1.8 [25]. In our study, >60.0% of
patients had elevated levels of LDH; furthermore, these
patients had significantly poorer 3-year OS rates com-
pared to those without elevated LDH levels (9.3% com-
pared to 22.6%). These pretreatment serum levels of
LDH may be a potential prognostic indicator.
In conclusion, we identified five independent prognos-
tic factors in NPC patients who initially presented with
liver metastasis. These included pretreatment perform-
ance status, LDH level, radiotherapy of the primary
tumor, the number of chemotherapy cycles and response
to chemotherapy. Although survival rates in these pa-
tients remains poor, our findings suggest that selected
patients may achieve improved survival by undergoing
comprehensive treatment, including six or more sys-
temic chemotherapy cycles and radiotherapy of the pri-
mary tumor. The application of local therapy to
metastatic lesions, in particular by RFA, may also pro-
long survival.Competing interests
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